INTRODUCTION

This lecture is designed to provide an overview of the diagnosis, treatment, and management of patients presenting with PH-ILD. Latest evidence from completed and ongoing clinical trials will be presented to identify therapeutic approaches useful in reducing the symptom burden of afflicted patients. Current treatment paradigms, their limitations, and new developments in PH-ILD will also be discussed.

Launch Date: March 10, 2021
Release Date: March 10, 2021
Expiration Date: February 28, 2022

TARGET AUDIENCE

This educational activity is strictly for healthcare providers who are involved in the clinical care of patients with pulmonary hypertension due to interstitial lung disease including physicians, physician assistants, registered nurses, nurse practitioners, and pharmacists.

LEARNING OBJECTIVES

Upon completion of this enduring material, participants should be able to:

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

• There are no fees for participating in and receiving credit for this enduring material.
• Review the learning objectives and activity information
• Review all modules associated with this activity
• Successfully complete the post-test ( accuracy or better).
• Complete the online evaluation.
• The estimated time to complete this enduring material is hour(s).
• Upon successful completion, your AMA or ANCC certificate will be emailed to you. ACPE credit will be posted to CPE Monitor.

ACCREDITATION STATEMENTS

PHYSICIANS
In support of improving patient care, Rush University Medical Center is jointly accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

NURSES
ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is contact hours.

PHARMACISTS
This activity is accredited for hour of continuing pharmacy education (CPE) credit. Rush University Medical Center will report all credit to CPE Monitor within 60 working days after receiving evidence of successful completion of the course.

RESOLUTION OF CONFLICT OF INTEREST

In accordance with the ACCME Standards for Commercial Support of CME, the Rush University Medical Center and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this accredited continuing education activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this activity.

DISCLOSURE

All planners and faculty participating in continuing education activities provided by the Rush University Medical Center are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the Rush University Medical Center.

The following speakers and/or planners have stated that they have the following financial relationship(s), and they have agreed to see that all information they planned and/or present is done so fairly and without bias:

DISCLOSURES

The accredited providers have mitigated and are disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

PLANNING COMMITTEE DISCLOSURE INFORMATION

Nothing to disclose
Sally Lemke, DNP, WHNP-BC
Jennifer Comerford
Mark Yoder, MD
Chris Fleming
Julia Peterson

FACULTY DISCLOSURES

Steven Nathan, MD
Advisory Committee/Board: Boehringer-Ingelheim, Roche-Genentech, United Therapeutics, Bellerophon, Third Pole, Pliant
Speaker Bureau: Boehringer-Ingelheim, Roche-Genentech, United Therapeutics
Consultant: Boehringer-Ingelheim, Roche-Genentech, United Therapeutics, Bellerophon, Third Pole, Pliant, Galapagos

DISCLAIMER

The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.

PRIVACY POLICY

The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.

Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

COPYRIGHT INFORMATION

Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.

HARDWARE/SOFTWARE REQUIREMENTS

• Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
• Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
• Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.

• Windows 7 or above running Internet Explorer 10 or above.
• MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
• A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.

• Any Apple iPad or iPad Mini running iOS 7.1 or above.
• Android tablets such as the Kindle Fire or Samsung Galaxy S.

COMMERCIAL SUPPORT ACKNOWLEDGMENT